Break Through to New Insights

AVISE SLE Monitor is a unique laboratory monitoring tool leveraging the power of Erythrocyte Bound C4d (EC4d) to help assess patients with SLE

AVISE SLE Monitor offers greater precision with:

  • EC4d: SLE disease activity biomarker measuring deposits resulting from complement activation
  • Anti-C1q: SLE disease activity and lupus nephritis monitoring marker 
  • Anti-dsDNA by CIA: Sensitive biomarker with superior association with disease activity compared to other methods
  • C3/C4: Major proteins of the complement process playing a key role in the inflammatory and immune system
  • PC4d Patented CB-CAP significantly associated with history of thrombosis and all-cause mortality 

AVISE SLE Monitor incorporates a powerful combination of disease activity markers to provide actionable results

EC4d Anti-C1q Anti-dsDNA by CIA
Erythrocyte-bound C4d (EC4d) measured by flow cytometry has been shown to significantly correlate with disease activity as measured by the clinical (non-immunological) SELENA-SLEDAI (p<0.01), SF-36 (p<0.01), and BILAG-2004 (p<0.05).1,3 EC4d is a stable biomarker to assess complement activation. Antibody levels to C1q have been shown to be significantly associated with clinical SELENA-SLEDAI values (p<0.05), lupus nephritis and proteinuria (p<0.01).3-4 Anti-C1q is a laboratory developed test validated by Exagen Diagnostics. The method of anti-dsDNA reported on the AVISE SLE Monitor test is a quantitative calibrated assay with an expanded dynamic range. This assay has demonstrated superior agreement with the Farr assay as well as correlation to disease activity, compared to other anti-dsDNA methods. 5-6
graph showing EC4d levels over time Graph showing Anti-C1q over time graph charting anti-dsDNA levels over time

Request more information on AVISE® testing


  1. Kao A, Navratil J, Ruffing M, et al. Erythocyte C3d and C4d for Monitoring Disease Activity in Systemic Lupus Erythematosus. Arthritis & Rheumatism. 2010.
  2. Buyon J, Furie R, Putterman C, et al. Reduction in erythrocyte-bound complement activation products and titers of Anti-C1q antibodies associated with clinical improvements in systemic lupus erythematosus. Lupus Science & Medicine. 2016.
  3. Merrill J, Petri M, Buyon J, et al. Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE. Lupus Science & Medicine. 2018.
  4. Mahler M, Bentow C, O’Malley T, et al. Performance Characteristics of Different Anti-Double-Stranded DNA Antibody Assays in the Monitoring of Systemic Lupus Erythematosus. J Immunol Res. 2017;2017:1720902.
  5. Petri M, Conklin J, Apilado R, et al. Complement C4d Split Products in Combination with Lupus Anticoagulant and Low Complement Associate with Thrombosis in SLE [abstract]. Arthritis Rheumatol. 2018; 70
  6. Kao A, McBurney C, Sattar A, et al. Relation of platelet C4d with all-cause mortality and ischemic stroke in patients with systemic lupus erythematosus. Transl Stroke Res 2014; 5(4):510-518
  7. Akhter E, Burlingame R, Seaman A, et al. Anti-C1Q antibodies have a higher correlation with flares of lupus nephritis than other serum markers. Lupus. 2012.
  8. Data on File Exagen Diagnostics 2018.

Pin It on Pinterest

Share This